TNFSF10 and obesity due to melanocortin 4 receptor deficiency: TRAIL receptor agonists as well as human recombinant TRAIL are currently tested for their anticancer activity in phase II clinical studies.9 Further research is needed to clarify if targeting the TRAIL/TRAIL-R system is a useful strategy to improve or restore adipose tissue function in the context of obesity.